Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88575279 |
LAW OFFICE ASSIGNED |
LAW OFFICE 117 |
MARK SECTION |
MARK |
APEXXNAR (see, http://uspto.report/TM/88575279/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
APEXXNAR |
OWNER SECTION (current) |
NAME |
Wyeth LLC |
MAILING ADDRESS |
235 East 42nd Street |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10017 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
212-733-2323 |
FAX |
212-573-2273 |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
Wyeth LLC |
MAILING ADDRESS |
235 East 42nd Street |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10017 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
212-733-2323 |
FAX |
212-573-2273 |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Richard A. Friedman |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
deadlinesipnyo@pfizer.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
deborah.melita@pfizer.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Richard A. Friedman |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
deadlinesipnyo@pfizer.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
deborah.melita@pfizer.com |
DOCKET/REFERENCE NUMBER |
T 427595 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic,
immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and
viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical
preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; human vaccine preparations |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
01/21/2020 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/RAF/ |
SIGNATORY'S NAME |
Richard A. Friedman |
SIGNATORY'S POSITION |
Attorney of Record |
DATE SIGNED |
12/29/2020 |
SIGNATORY'S PHONE NUMBER |
212-733-0086 |
FILING INFORMATION |
SUBMIT DATE |
Tue Dec 29 15:00:45 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXX.XXX.XX.XXX-
20201229150045782525-8857
5279-75018842a1857079a242
1cd7556f2ff6ec847aa7e1ba7
86381b2654ed372973f9d-DA-
00456601-2020122914521720
7650 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: APEXXNAR (see, http://uspto.report/TM/88575279/mark.png)
SERIAL NUMBER: 88575279
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Wyeth LLC, having an address of
235 East 42nd Street
New York, New York 10017
United States
Phone: 212-733-2323
Fax: 212-573-2273
Email: XXXX
Proposed: Wyeth LLC, having an address of
235 East 42nd Street
New York, New York 10017
United States
Phone: 212-733-2323
Fax: 212-573-2273
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 01/21/2020.
For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious,
inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and
disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely,
antifungal preparations, dermatological preparations and smoking cessation preparations; human vaccine preparations
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
Richard A. Friedman
PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): deborah.melita@pfizer.com
Correspondence Information (proposed):
Richard A. Friedman
PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): deborah.melita@pfizer.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /RAF/ Date Signed: 12/29/2020
Signatory's Name: Richard A. Friedman
Signatory's Position: Attorney of Record
Signatory's Phone: 212-733-0086
RAM Sale Number: 88575279
RAM Accounting Date: 12/29/2020
Serial Number: 88575279
Internet Transmission Date: Tue Dec 29 15:00:45 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.XXX-202012291500457
82525-88575279-75018842a1857079a2421cd75
56f2ff6ec847aa7e1ba786381b2654ed372973f9
d-DA-00456601-20201229145217207650